

For Public Release

NZX Limited
Wellington

17 November 2022

Amendments to Governance Policies

The board of Cannasouth Limited has changed responsibility for governance of risk from the Audit and Finance Committee Charter to the Governance Code, thereby focusing the committee on finance and audit. Governance and general business risks remains a full board activity.

The board has adopted a new Financial Products Trading policy, to replace its existing policy.

These amendments are reflected in the governance documents that can be found on the Cannasouth website: <https://www.cannasouth.co.nz/investors/governance/>

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO / Executive Director

Email: mark.lucas@cannasouth.co.nz

Mobile: 021 484 649

Colin Foster

CFO / Company Secretary

Email: colin.foster@cannasouth.co.nz

Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products will be produced under GxP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd, and Midwest Pharmaceuticals NZ Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>